Pneumococcal Vaccines 2024
The U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the U.K.'s NHS have approved vaccines to prevent pneumococcal disease. The World Health Organization (WHO) says pneumococcal vaccination prevents pneumococcal disease caused by Streptococcus pneumoniae, a bacterium with more than 90 serotypes. While vaccines can not prevent every kind of community-acquired pneumonia, they work against the thirty most common bacteria types. On October 24, 2023, the New England Journal of Medicine published a Review article: The Present and Future of the Adult Pneumococcal Vaccine Program in the U.S. According to Prophecy Market Insights in May 2023, the Pneumococcal Vaccine Market is anticipated to register a ten-year CAGR of 5.3%.
Pneumococcal Vaccine Recommendations U.S. CDC
The U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) met on February 29, 2024, and reviewed various presentations. On October 26, 2023, Miwako Kobayashi, MD, MPH, led a pneumococcal ACIP workgroup vaccine update. On June 22, 2023, ACIP presentations: Economic Assessment of Routine PCV20 for Children; Summary of three economic analyses of the use of the 20-valent pneumococcal conjugate vaccine (PCV20) in children in the U.S.; Evidence to Recommendations Framework and Policy Options: Use of 20-valent Pneumococcal Conjugate Vaccine in U.S. Children. The U.S. CDC's pneumococcal vaccine schedules were updated in 2023.
On February 22, 2023, Katherine A. Poehling, MD, MPH Pneumococcal Vaccines Work Group Chair, led the following presentations: Current Epidemiology of Pediatric Pneumococcal Disease, Pediatric outpatient ARI visits and antibiotic use attributable to serotypes in higher valency PCVs, Pfizer's 20 -valent Pneumococcal Conjugate Vaccine (PCV20) Phase 3 in Pediatrics, Evidence to Recommendations Framework (Preliminary): Use of 20-valent Pneumococcal Conjugate Vaccine in U.S. Children, Pneumococcal Vaccines Work Group Considerations and Next Steps.
On October 19, 2022, and reviewed the following presentations: Introduction; Economic Assessment of PCV20 for Adults Vaccinated with PCV13; Evidence to Recommendations Framework: PCV20 Use among Adults who Previously Received PCV13; Updates to Clinical Guidance. On June 22, 2022, the ACIP committee presented the following information: PCV15 Pediatric Clinical Development Program – Dr. N Banniettis; Economic analysis and public health impact of PCV15 use among children in the U.S. - Dr. A Leidner; Summary of W.G. interpretation on EtR and Proposed recommendations for PCV15 use in children by Dr. M Kobayashi. Furthermore, the CDC recommends that all adults 65 years and older and adults with underlying medical conditions receive one dose of PCV15 or one dose of PCV20. On September 16, 2022, the CDC published: Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the ACIP — the United States, 2022.
Pneumococcal Vaccines Approved
Pneumovax 23™ is a vaccine that protects against infection by 23 types of pneumococcal bacteria, common and often cause serious illnesses.
Prevnar 20® is a newly approved vaccine that is indicated for active immunization to prevent pneumonia and invasive diseases.
Prevnar 13® is a vaccine that protects against invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.
VAXNEUVANCE™ is a 15-valent pneumococcal conjugate vaccine and is U.S. FDA-approved.
Synflorix PCV10 is a decavalent vaccine containing ten serotypes of pneumococcus conjugated to a carrier protein produced by GlaxoSmithKline. Synflorix received a positive opinion from the European Medicines Agency for use in the European Union in January 2009.
Sinovac PPV23 is a Chinese vaccine that protects adults and children ages two and older against infection by 23 types of pneumococcal bacteria.
Serum Institute of India PNEUMOSIL is a PCV, adsorbed, 10 Valent, a well-designed vaccine with relevant serotypes and provides comparable protection by targeting the most prevalent serotypes bacterium causing severe illness in developing countries. PNEUMOSIL is approved for use in infants and toddlers from 6 weeks to 2 years of age, conducting phase 3 studies.
Pneumococcal Vaccine Candidates
Vaxcyte Inc. investigational pneumococcal conjugate vaccines prevent IPD and pneumonia. VAX-24 is an investigational 24-valent PCV candidate designed to avoid IPD, which can be most serious for infants, young children, older adults, and those with immune deficiencies or certain chronic health conditions. VAX-31 is a 31-valent Pneumococcal Conjugate Vaccine Designed to Provide Coverage for Approximately 95% of diseases currently circulating in the U.S. Adult Population. On November 9, 2023, the first participants were dosed in a Phase 1/2 clinical study for VAX-31.
Merck's 21-valent pneumococcal conjugate vaccine candidate V116 is designed to prevent IPD and pneumococcal pneumonia caused by 21 Streptococcus pneumoniae serotypes.
Affinivax, Inc. and Astellas Pharma Inc. - ASP3772, a novel vaccine candidate, targets Streptococcus pneumoniae. ASP3772 offers B-cell (antibody) and T-cell immune protection against Streptococcus pneumoniae. In addition, ASP3772 includes 24 pneumococcal polysaccharides, as well as two conserved pneumococcal proteins. The U.S. Food and Drug Administration has also granted Breakthrough Therapy designation for ASP3772 to prevent pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes included in ASP3772 in adults aged 50 years older.
Inventprise IVT-PCV-25 is an investigational 25 valent PCV designed to include the key strains that cause serious invasive diseases in childrInventprise is developing IVT-PCV-25cination in their Phase 2 dose-ranging study of its in young adults as of January 2, 2023. IVT-PCV-25 is being developed by Inventprise in collaboration with the non-profit global health organization PATH.
Note: This content is reviewed by healthcare professionals such as Dr. Robert Carlson.
